These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32537492)
1. A VersaTile-driven platform for rapid hit-to-lead development of engineered lysins. Gerstmans H; Grimon D; Gutiérrez D; Lood C; Rodríguez A; van Noort V; Lammertyn J; Lavigne R; Briers Y Sci Adv; 2020 Jun; 6(23):eaaz1136. PubMed ID: 32537492 [TBL] [Abstract][Full Text] [Related]
2. Engineering a Lysin with Intrinsic Antibacterial Activity (LysMK34) by Cecropin A Fusion Enhances Its Antibacterial Properties against Acinetobacter baumannii. Abdelkader K; Gutiérrez D; Tamés-Caunedo H; Ruas-Madiedo P; Safaan A; Khairalla AS; Gaber Y; Dishisha T; Briers Y Appl Environ Microbiol; 2022 Jan; 88(1):e0151521. PubMed ID: 34669452 [TBL] [Abstract][Full Text] [Related]
3. Rapid and High-Throughput Evaluation of Diverse Configurations of Engineered Lysins Using the VersaTile Technique. Duyvejonck L; Gerstmans H; Stock M; Grimon D; Lavigne R; Briers Y Antibiotics (Basel); 2021 Mar; 10(3):. PubMed ID: 33799561 [TBL] [Abstract][Full Text] [Related]
5. Antibacterial Activity of a Novel Peptide-Modified Lysin Against Acinetobacter baumannii and Pseudomonas aeruginosa. Yang H; Wang M; Yu J; Wei H Front Microbiol; 2015; 6():1471. PubMed ID: 26733995 [TBL] [Abstract][Full Text] [Related]
6. Membrane-Permeable Antibacterial Enzyme against Multidrug-Resistant Chen X; Liu M; Zhang P; Leung SSY; Xia J ACS Infect Dis; 2021 Aug; 7(8):2192-2204. PubMed ID: 34232613 [TBL] [Abstract][Full Text] [Related]
7. Recombinant bacteriophage lysins as antibacterials. Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123 [TBL] [Abstract][Full Text] [Related]
8. Identification of Three Campylobacter Lysins and Enhancement of Their Anti-Escherichia coli Efficacy Using Colicin-Based Translocation and Receptor-Binding Domain Fusion. Liu P; Dong X; Cao X; Xie Q; Huang X; Jiang J; Dai H; Tang Z; Lin Y; Feng S; Luo K Microbiol Spectr; 2023 Feb; 11(2):e0451522. PubMed ID: 36749047 [TBL] [Abstract][Full Text] [Related]
10. Engineered bacteriophage lysins as novel anti-infectives. Yang H; Yu J; Wei H Front Microbiol; 2014; 5():542. PubMed ID: 25360133 [TBL] [Abstract][Full Text] [Related]
11. Bacteriophage-derived endolysins to target gram-negative bacteria. Lai WCB; Chen X; Ho MKY; Xia J; Leung SSY Int J Pharm; 2020 Nov; 589():119833. PubMed ID: 32877733 [TBL] [Abstract][Full Text] [Related]
12. Engineered Lysins With Customized Lytic Activities Against Enterococci and Staphylococci. Binte Muhammad Jai HS; Dam LC; Tay LS; Koh JJW; Loo HL; Kline KA; Goh BC Front Microbiol; 2020; 11():574739. PubMed ID: 33324362 [TBL] [Abstract][Full Text] [Related]
13. Lysin LysMK34 of Abdelkader K; Gutiérrez D; Grimon D; Ruas-Madiedo P; Lood C; Lavigne R; Safaan A; Khairalla AS; Gaber Y; Dishisha T; Briers Y Appl Environ Microbiol; 2020 Sep; 86(19):. PubMed ID: 32709718 [TBL] [Abstract][Full Text] [Related]